open access

Ahead of print
Original papers
Published online: 2019-05-27
Submitted: 2019-01-03
Accepted: 2019-04-29
Get Citation

BRAF V600E Mutation in Papillary Thyroid Cancer is Correlated with Adverse Clinicopathological Features but not with Iodine Exposure

Serhat Özçelik, Rifat Bircan, Şükran Sarıkaya, Aylin Ege Gül, Büşra Aydın, Melike Özçelik, Mehmet Çelik, Akın Dayan, Yasemin Tütüncü, Hasret Cengiz, Nimet Karadayı, Hülya Gözü
DOI: 10.5603/EP.a2019.0025
·
Pubmed: 31135058

open access

Ahead of print
Original papers
Published online: 2019-05-27
Submitted: 2019-01-03
Accepted: 2019-04-29

Abstract

Aim: BRAF V600E activating mutation is the most frequent genetic abnormality in the pathogenesis of papillary thyroid carcinoma. We aimed to evaluate the association between BRAF V600E mutation and well-established prognostic clinicopathological characteristics as well as the iodine exposure. Materials and Methods: From 2000 to 2012, the data of PTC patients admitted to Dr. Lutfi Kirdar Kartal Education and Research Hospital, Turkey, were reviewed retrospectively. Clinicopathological parameters were collected. BRAF V600E mutation was analyzed by polymerase chain reaction method in tumor specimens. We hypothesized that BRAF V600E mutation prevalance is positively correlated with prolonged iodine exposure and expected to be higher in the second half of the recruitment period due to the increment in time spent from the iodinization process of the table salt in our country. Thus, iodine exposure was categorized as short-term (2000-2006) and long-term (2006-2012). Results: A total of 197 patients were accrued. The study population predominantly consisted of conventional subtype. A statistically significant relationship was observed between BRAF V600E mutation presence and age (p=0.03) conventional type PTC (p=0.00002), T4 stage (p<0.00001), vascular invasion (p=0.036), thyroid capsule invasion (p<0.00001), extrathyroidal tissue invasion (p<0.00001) and lymph node metastasis (p<0.00001). When categorized as long-term and short-term, iodine exposure, was not statistically significantly related with BRAF V600E mutation however, there were far more PTC cases in the long-term group (86.3% vs.13.7%). Conclusion: We revealed that BRAFV600E mutation is associated with adverse clinicopathological parameters. Unlikely, there appeared to be no relation with long-term iodine exposure and BRAF V600E.

Abstract

Aim: BRAF V600E activating mutation is the most frequent genetic abnormality in the pathogenesis of papillary thyroid carcinoma. We aimed to evaluate the association between BRAF V600E mutation and well-established prognostic clinicopathological characteristics as well as the iodine exposure. Materials and Methods: From 2000 to 2012, the data of PTC patients admitted to Dr. Lutfi Kirdar Kartal Education and Research Hospital, Turkey, were reviewed retrospectively. Clinicopathological parameters were collected. BRAF V600E mutation was analyzed by polymerase chain reaction method in tumor specimens. We hypothesized that BRAF V600E mutation prevalance is positively correlated with prolonged iodine exposure and expected to be higher in the second half of the recruitment period due to the increment in time spent from the iodinization process of the table salt in our country. Thus, iodine exposure was categorized as short-term (2000-2006) and long-term (2006-2012). Results: A total of 197 patients were accrued. The study population predominantly consisted of conventional subtype. A statistically significant relationship was observed between BRAF V600E mutation presence and age (p=0.03) conventional type PTC (p=0.00002), T4 stage (p<0.00001), vascular invasion (p=0.036), thyroid capsule invasion (p<0.00001), extrathyroidal tissue invasion (p<0.00001) and lymph node metastasis (p<0.00001). When categorized as long-term and short-term, iodine exposure, was not statistically significantly related with BRAF V600E mutation however, there were far more PTC cases in the long-term group (86.3% vs.13.7%). Conclusion: We revealed that BRAFV600E mutation is associated with adverse clinicopathological parameters. Unlikely, there appeared to be no relation with long-term iodine exposure and BRAF V600E.

Get Citation

Keywords

Papillary thyroid cancer, BRAF V600E, iodine

About this article
Title

BRAF V600E Mutation in Papillary Thyroid Cancer is Correlated with Adverse Clinicopathological Features but not with Iodine Exposure

Journal

Endokrynologia Polska

Issue

Ahead of print

Published online

2019-05-27

DOI

10.5603/EP.a2019.0025

Pubmed

31135058

Keywords

Papillary thyroid cancer
BRAF V600E
iodine

Authors

Serhat Özçelik
Rifat Bircan
Şükran Sarıkaya
Aylin Ege Gül
Büşra Aydın
Melike Özçelik
Mehmet Çelik
Akın Dayan
Yasemin Tütüncü
Hasret Cengiz
Nimet Karadayı
Hülya Gözü

References (31)
  1. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998; 83(12): 2638–2648.
  2. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001; 8(6): 345–354.
  3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949–954.
  4. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95(8): 625–627.
  5. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003; 63(15): 4561–4567.
  6. Suzuki K, Mitsutake N, Saenko V, et al. Radiation signatures in childhood thyroid cancers after the Chernobyl accident: possible roles of radiation in carcinogenesis. Cancer Sci. 2015; 106(2): 127–133.
  7. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009; 94(5): 1612–1617.
  8. Erdoğan G, Erdogan MF, Emral R. Iodine status and goiter prevalence in Turkey before mandatory iodinization. J Endocrinol Invest. 2002; 25(3): 224–228.
  9. Erdoğan MF, Ağbaht K, Altunsu T, et al. Current iodine status in Turkey. J Endocrinol Invest. 2009; 32(7): 617–622.
  10. Hacettepe University Instute of Population Studies Ministry of Health. Turkey Demographic and Health Survey Iodization of table salts. Turkey, Ankara 2003: 145–147.
  11. Gozu HI, Bircan R, Krohn K, et al. Similar prevalence of somatic TSH receptor and Gsalpha mutations in toxic thyroid nodules in geographical regions with different iodine supply in Turkey. Eur J Endocrinol. 2006; 155(4): 535–545.
  12. Qu K, Pan Q, Zhang Xi, et al. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays. J Mol Diagn. 2013; 15(6): 790–795.
  13. Rosenthal A, Coutelle O, Craxton M. Large-scale production of DNA sequencing templates by microtitre format PCR. Nucleic Acids Res. 1993; 21(1): 173–174.
  14. Kordes M, Röring M, Heining C, et al. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia. 2016; 30(4): 937–946.
  15. Park JiH, Kwon HJu, Park CS, et al. Anaplastic Transformation of Papillary Thyroid Carcinoma in a Young Man: A Case Study with Immunohistochemical and BRAF Analysis. Korean J Pathol. 2014; 48(3): 234–240.
  16. Russo M, Malandrino P, Nicolosi ML, et al. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome. Thyroid. 2014; 24(8): 1267–1274.
  17. Guerra A, Fugazzola L, Marotta V, et al. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab. 2012; 97(7): 2333–2340.
  18. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013; 309(14): 1493–1501.
  19. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007; 246(3): 466–70; discussion 470.
  20. Chen Y, Sadow PM, Suh H, et al. BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. Thyroid. 2016; 26(2): 248–255.
  21. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015; 33(1): 42–50.
  22. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007; 110(1): 38–46.
  23. Smith RA, Salajegheh A, Weinstein S, et al. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol. 2011; 42(4): 500–506.
  24. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88(11): 5399–5404.
  25. Lu H, Qiu T, Ying J, et al. [Correlation between BRAF V600E mutation and clinicopathologic features of papillary thyroid carcinoma]. Zhonghua Bing Li Xue Za Zhi. 2014; 43(12): 794–798.
  26. Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid. 2013; 23(11): 1423–1430.
  27. Lang BH, Chai YJ, Cowling BJ, et al. Is BRAFV600E mutation a marker for central nodal metastasis in small papillary thyroid carcinoma? Endocr Relat Cancer. 2014; 21(2): 285–295.
  28. Navarro-Locsin CG, Chang AMV, Daroy ML, et al. Clinical and histopathological profile of BRAF V600E mutation in conventional papillary thyroid carcinoma in a Filipino population. Malays J Pathol. 2016; 38(2): 141–148.
  29. Smyth P, Finn S, Cahill S, et al. ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma. Int J Surg Pathol. 2005; 13(1): 1–8.
  30. Daniell K, Nucera C. Effect of the micronutrient iodine in thyroid carcinoma angiogenesis. Aging (Albany NY). 2016; 8(12): 3180–3184.
  31. Frasca F, Nucera C, Pellegriti G, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008; 15(1): 191–205.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl